Charles S. Craik, PhD
Principal Investigator
[email protected]

My research focuses on structure-function analysis of proteases and their inhibitors. In my lab we use a combination of genetic, biochemical, and biophysical methods, with particular emphasis on identifying the roles and regulating the activity of proteases associated with infectious diseases, cancer, and development.


Beatrice Ary
[email protected]

I received my BA in Chemistry concentrating in Biochemistry from Bryn Mawr College. During my undergraduate, I researched the biophysical properties of a human derived peptidic hydrogel for potential applications in medical therapies with Karin Åkerfeldt at Haverford College. My research in the Craik Lab focuses on the host pathogen interface and creating chemical tools to study dynamic protein protein interactions.


Markus-Frederik Bohn, PhD
[email protected]

I performed my PhD research at UMass Medical School on structure and biochemistry of APOBEC3 enzymes in the lab of Celia Schiffer. Thematically, I am interested in identifying novel therapeutic targets for antiviral strategies at the host-pathogen interface. Methodologically, I work at the interface between structural biology and data analytics, establishing new models for structure-function relationships of enzymatic activity. With my research I hope to elevate molecules that serve analytical, diagnostic, and therapeutic purposes to the next level of precision-engineered tools.


Francesco Caiazza, PhD
[email protected]

I received my MSc in Biology from Roma Tre University, and a PhD in Molecular Medicine from RCSI with Maria Marino and Bryan Harvey, studying the molecular changes associated with steroid signaling in endocrine-dependent tumors. My postdoc training at UCD started with Joe Duffy in the MTCI Consortium to investigate therapeutic targets for triple-negative breast cancer, then in the lab of Liz Ryan and Glen Doherty to work on resistance to targeted therapy in colorectal cancer. I joined the Craik lab in 2016, applying a protease profiling strategy (MSP-MS) to discover proteolytic signatures associated with colon cancer subtypes and progression. I collaborate with Alaunus Biosciences (co-founded by Craik) to leverage the unique protease activity signatures in the tumor microenvironment for development of protease-based diagnostic and therapeutic biomarkers. My interest broadly lies in translational research applied to oncology, at the intersection of the academic and entrepreneurial worlds.


Dong-Hee Chung, PhD
[email protected]

I received my BA in Chemistry from Kyung Hee University (Seoul, South Korea) and PhD in Chemistry from the University of California, Davis. My PhD research focused on deciphering the mechanism of how substrate and reaction specificities are controlled in two classes of enzymes, chorismate utilizing enzymes and PLP-enzymes. I developed a novel multi-site-specific mutagenesis method to assist in a bioinformatics tool Janus, where key residues predicted to be important for substrate and reaction specificity were randomly mutated. Currently, I am interested in designing next generation phage displayed fab libraries for the rapid identification of high affinity Fabs against specific conformations of transmembrane proteins, proteases involved in various cancers, and DNA. With newly discovered Fabs, I hope to elucidate new fab-target interactions and further utilize them for various applications.


Efrat Harel, PhD
[email protected]

I received my BSc in molecular biochemistry (2006, Technion Israel Institute of Technology) and PhD in pharmaceutical sciences (2013, The Hebrew University of Jerusalem) in the labs of Abraham Rubinstein and Boaz Tirosh. For my graduate research, I identified and targeted biomarkers in inflamed gut epithelial tissue with liposomal drug delivery systems. I am currently focusing on utilizing anti-urokinase plasminogen activator receptor (uPAR) antagonist antibodies in addition to developing new anti-uPAR constructs.


Kaitlin Hulce
[email protected]

I received my BS in chemistry and biology from Brandeis University. While there, I worked with Dr. Jason Pontrello the synthesis of polymeric glutamine displays to mediate huntingtin protein aggregation and study its role in Huntington’s disease progression. I later worked with Dr. Lizbeth Hedstrom on inhibitor-mediated protein degradation, specifically designing an arginine-linked methotrexate analogue to target dihydrofolate reductase for degradation. I am currently a PhD candidate, working in the Craik Lab to develop Cysteine-targeted inhibitors of herpes virus proteases. My interests are in studying the enzymology and structure-function of this dynamic class of enzymes, as well as in rational inhibitor design to disrupt the herpes viral lifecycle.

Luiz Laurenco

André Luiz Lourenço, PhD
[email protected]

I received my BS in development biosciences and my Msc in pathology from the Fluminense Federal University (Rio de Janeiro, Brazil). During my PhD I focused on the development of Restricted-Interaction Peptides (RIPs) for the non-invasive imaging of threatening blood clots in vivo through near-infrared (NIR) fluorescence and positron-emission tomography (PET). My research interests lie in the understanding of disease-associated proteolysis, particularly in cardiovascular diseases and cancer, to proper optimize our RIP technology toward clinical translation.


Matt Ravalin
[email protected]

My research interests center on the interface of cellular proteolysis and proteostasis. In particular, I am interested in understanding the emergent properties of products of protease activity and how these neo-epitopes interact with cellular proteostasis networks. I am using global and candidate-based approaches to characterize nodes at which proteolysis and proteostasis intersect, and I am exploring this interplay in the context of neurodegenerative disease. Prior to coming to UCSF to begin my doctoral work, I spent five years working in industrial drug discovery in San Diego after receiving by BS from UC San Diego. I try to spend as much of my free time as possible fishing, hiking, and generally enjoying the outdoors.


Peter Rohweder
[email protected]

I received my BA in Chemistry at The College of Wooster in 2016. My undergraduate research focused on the development of synthetic methods for the chiral control of the Ugi multicomponent reaction. In my graduate research, I am interested in the development of safer therapeutics for cancer. Specifically, I am using our recently developed MSP-MS technology for the global characterization of misregulated proteolysis in breast cancer to enable the development of protease activated prodrugs. Additionally, I am interested in using antibody engineering approaches for the development of safer immunotherapies.


Marcell Zimanyi
[email protected]

My research is focused on developing antibody based platforms to study the structure and function of proteases and membrane proteins. More specifically, I use phage displayed libraries to isolate and affinity mature antibodies to a broad range of targets, and then apply them as biochemical assay tools, chaperones for structural biology, and drug and diagnostics development. I also work at the Advanced Light Source in Berkeley where I am helping advance hydroxyl radical footprinting, a technique I use to rapidly identify the epitopes of our antibodies. Before joining the lab I worked at Bayer for 2 years in the Hematology discovery group. I earned my degree in Molecular and Cell biology with an emphasis in Neurobiology from UC Berkeley, where I researched the neural correlates of taste in drosophila.






Lili Li
[email protected]

Serve as point of contact for administrative inquiries; support administrative needs; coordinate visits from guest speakers; manage calendars


Related link